MicroRNAs As Master Regulators of Atherosclerosis: From Pathogenesis to Novel Therapeutic Options
Authors:
- 13 August 2020
- journal article
- research article
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 33 (9) , 621-644
Abstract
Significance: Cardiovascular disease (CVD) remains the major cause of morbidity and mortality worldwide. Accumulating evidence indicates that atherosclerosis and its sequelae, coronary artery disease, contribute to the majority of cardiovascular deaths. Atherosclerosis is a chronic inflammatory disease of the arteries in which atherosclerotic plaques form within the vessel wall. Epidemiological studies have identified various risk factors for atherosclerosis, such as diabetes, hyperlipidemia, smoking, genetic predisposition, and sedentary lifestyle. Recent Advances: Through the advancement of genetic manipulation techniques and their use in cardiovascular biology, it was shown that small RNAs, especially microRNAs (miRNAs), are dynamic regulators of disease pathogenesis. They are considered to be central during the regulation of gene expression through numerous mechanisms and provide a means to develop biomarkers and therapeutic tools for the diagnosis and therapy of atherosclerosis. Circulating miRNAs encapsulated within membrane-surrounded vesicles, which originate from diverse subcellular compartments, are now emerging as novel regulators of intercellular communication. The miRNAs, in both freely circulating and vesicle-bound forms, represent a valuable tool for diagnosing and monitoring CVD, recently termed as “liquid biopsy.” Critical Issues: However, despite the recent advancements in miRNA-based diagnostics and therapeutics, understanding how miRNAs can regulate atherosclerosis is still crucial to achieving an effective intervention and reducing the disease burden. Future Directions: We provide a landscape of the current developmental progression of RNA therapeutics as a holistic approach for treating CVD in different animal models and clinical trials. Future interrogations are warranted for the development of miRNA-based therapeutics to overcome challenges for the treatment of the disease.Keywords
This publication has 187 references indexed in Scilit:
- MicroRNA therapeutics in cardiovascular medicineEMBO Molecular Medicine, 2011
- Basic and Therapeutic Aspects of AngiogenesisCell, 2011
- MicroRNA-503 and the Extended MicroRNA-16 Family in AngiogenesisTrends in Cardiovascular Medicine, 2011
- MicroRNA‐26a is a novel regulator of vascular smooth muscle cell functionJournal of Cellular Physiology, 2010
- Secreted Monocytic miR-150 Enhances Targeted Endothelial Cell MigrationMolecular Cell, 2010
- MicroRNA-21 in Cardiovascular DiseaseJournal of Cardiovascular Translational Research, 2010
- MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activityBiochemical and Biophysical Research Communications, 2010
- miR-296 Regulates Growth Factor Receptor Overexpression in Angiogenic Endothelial CellsCancer Cell, 2008
- miR-126 Regulates Angiogenic Signaling and Vascular IntegrityDevelopmental Cell, 2008
- The Endothelial-Specific MicroRNA miR-126 Governs Vascular Integrity and AngiogenesisDevelopmental Cell, 2008